ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – STUB GlobeNewswire December 06, 2025 NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. […]

Emerging tests and treatment strategies guide more tailored approaches and ease the burden on patients Four clinical trials to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition illustrate how advancements in technology are contributing to an improved outlook for many patients with blood cancers. https://mma.prnewswire.com/media/347783/American_Society_of_Hematology_logo.jpg “These studies tie together

(NASDAQ:ADPT), SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of its clonoSEQ(R) test among the 90 abstracts featuring clonoSEQ data at the 67th

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ(R) Data Driving Treatment Interventions at 2025 ASH Annual Meeting GlobeNewswire December 06, 2025 SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Sprouts to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Sprouts between June 4, 2025 and October 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Marex to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Marex between May 16, 2024 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Alexandria to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Alexandria between January 27, 2025 and October 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

(NASDAQ:ARVN), – Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN, Conn., Dec. 06, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating

SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today collaborative presentations at the 67th American Society of Hematology Annual Meeting and Exposition, in Orlando, Florida; with scientists from the Duke University School of Medicine in Durham, North Carolina; reporting data from preclinical

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition GlobeNewswire December 06, 2025 – Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a